CVC  Cato BioVentures

http://www.catobioventures.com





     Office Locations:

4364 South Alston Avenue
Durham, NC 27713
Phone: 919-361-2286
Fax: 919-361-2290

 

Stages:

  • Early
  • Expansion
  • Growth
  • Middle Market


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Cato BioVentures is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization (CRO). For over 25 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotech and pharmaceutical companies to advance a robust portfolio of sucessful product development programs. The firm focuses on early to mid-stage investment opportunities in private companies and undervalued public companies. Through strategic CRO service agreements with Cato Research, the firm has invested its 'CRO Service Capital' in innovative therapeutics, medical devices and stem cell technologies that improve Pharma's Research and Development productivity. Cato focuses on high value life science investment opportunities at all stages of development and across multiple therapeutic and technical areas. The firm is uniquely interested in product development opportunities in undervalued public companies that have gone off track or fallen out of favor with the investment community for technical reasons.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Allen Cato MD, PhD Principal
    Daniel Pharand CA Principal
    Jo Cato PhD Vice President
    Lynda Sutton BS Principal
    Michael Cato MS, RAC Vice President

     

    Portfolio companies include:


      Abeome
        web link


      Advanced Pain Remedies
        web link


      Alseres
        web link


      BioMarck
        web link


      Biothera
        web link


      Cancer Advances
        web link


      Catena
        web link


      Compellis
        web link


      CordexPharma
        web link


      Cumberland Pharmaceuticals
        web link


      Cytos
        web link


      Echo Therapeutics
        web link


      Emmaus Medical
        web link


      EntreMed
        web link


      etrials
        web link


      FR
        web link


      Hemodynamic
        web link


      IMV
        web link


      InnerOptic
        web link


      Mithridion
        web link


      Neuren Pharmaceuticals
        web link


      SanoGene
        web link


      Senesco
        web link


      VistaGen
        web link


     

    Recent News: